IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

680

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Melanoma

Interventions

DRUG: Brenetafusp
DRUG: Nivolumab
DRUG: Nivolumab + Relatlimab

Sponsor

Immunocore Ltd